Nonetheless, Vir is showing remarkable agility by starting promising coronavirus therapeutics programs while pushing its prior hepatitis B project into phase 1 clinical trials.Where other biotechs might aim for the moon with drug development programs based on unproven or uncertain science, Vir seems content to turn well-understood scientific concepts into uncontroversial yet highly effective products.